The national key monitoring catalogue is adjusted every two years, and Chinese medicine companies look to the non-medical insurance market

Medical Network News, August 12 On August 6, it is reported that relevant departments have recently issued a draft for the adjustment of the auxiliary drug catalogue to the provinces.
The main contents are as follows: 1.
Catalogue adjustment frequency: dynamic adjustment, once every two years
.
2.
The scope of inclusion in the catalogue: According to the price and dosage of the medicine , the key is to lock the large dosage, high amount, easy clinical abuse, and clinical auxiliary drugs
.
3.
Number of catalogs: about 30+
.
4.
Adjustment process: medical institutions report based on existing medications, and report collectively at the provincial level
.

The hospital market is shrinking.

On July 1, 2019, the Medical Administration and Hospital Administration of the National Health Commission issued the first batch of national key monitoring and rational use drugs (chemical drugs and biological products) notice
.
According to statistics, the first batch of 20 drugs entered the national key monitoring and rational use drug list
.
In the new version of the National Medical Insurance Catalogue published in August 2019, all key monitored drugs are transferred, including some varieties with relatively large annual sales, which may have an impact on the production and operation of individual enterprises
.
Public data shows that the total sales data of sample hospitals of these 20 key monitoring varieties in 2018 was 17.
6 billion yuan, but the market size has dropped from 37 billion yuan in 2019 to 11 billion yuan in 2020, a drop of nearly 80%
.
Provinces continue to add provincial key monitoring catalogs, which will become candidates for national key monitoring catalogs
.
Once the product enters the key monitoring, it will face lowering the online price, and adjust the maximum sales price and medical insurance payment standards accordingly
.
As of August 6, 11 hospitals in 22 provinces, 17 cities, and 11 hospitals have published the list of key monitored drugs, involving 203 varieties
.
Judging from the catalogs published by the provinces, Inner Mongolia, Heilongjiang, Guangdong, Jiangsu, Sichuan, Shaanxi, Guizhou, Gansu, Jilin, Hubei, Yunnan, Fujian, Shanghai, and Tibet are consistent with the national catalog
.
In addition to the national version, Jiangxi added 15 new ones, Hebei added 5 new ones, Hainan added 10 new ones, Shanxi added 2 new ones, Xinjiang added 14 new ones, Zhejiang added 12 new ones, Anhui added 2 new ones, Guangxi added new ones 5, Qinghai increased by 10, Xinjiang Corps increased by 13 varieties
.
According to the key monitoring products in some provinces, traditional Chinese medicine injections and auxiliary drugs have become the first choices for the development of key monitoring catalogs in various provinces.
Nutritional drugs, antibiotics and some anti-tumor varieties have also appeared in the lists of different provinces
.


What to do after the company's varieties of the 　　combination drug program are under key monitoring? According to the attributes of the variety, pharmaceutical companies can actively prove whether the variety meets the key monitoring conditions through pharmacoeconomics, clinical research, etc.
, actively reduce the bid price, control sales, and reduce the possibility of the variety being included in the key monitoring
.
If the product is designated as the second batch of key monitoring products, it is recommended that the company first protect the hospital
.
According to the screening rules of key monitoring products, such as large consumption, high amount, easy clinical abuse, and clinical auxiliary drugs, the decline in sales in the hospital is inevitable
.
However, if the unique value of drugs can be found in the clinical pathway, and more effective treatment options can be locked in new research on combination drugs, it is possible to continue to protect the in-patient market without a rapid decline in sales
.
Judging from the sales results of the first batch of national key monitoring products, although the sales of key monitoring products have fallen by more than 70% in hospitals, there is still nearly 30% of the stock market, indicating that the key monitoring products still have a certain market and therapeutic value in the hospital.

.
Therefore, what measures should be adopted to protect the in-patient market is the first issue to be considered
.
At the same time as protecting the hospital, the outside of the hospital must also be expanded
.
The key monitoring varieties have a certain prescription basis and patient population, and the effects of many varieties are still very good
.
Although the sales of drugs in the hospital are declining under the key monitoring, it can be compensated by the out-of-hospital clinical sales model by placing the varieties in DTP pharmacies outside the hospital for outsourcing
.
The out-of-hospital clinical model is the only way to separate medicine .
Enterprises can seek cooperation with commercial insurance as a supplement to medical insurance
.

　　Focusing on the non-medical insurance market,
pharmaceutical companies focus on monitoring and restricting the use of drugs, ranging from a sharp decline in sales performance to a break in the capital chain
.
But "the East is not bright, the West is bright", in addition to public hospitals, there are also private hospitals, clinics, chain pharmacies, single pharmacies and other channels that can be opened up
.
Restricted varieties open up a "second battlefield", and you can consider switching from medical insurance drugs to self-paid drugs in public hospitals
.
Oral drugs that have been sold in hospitals for many years and have a solid market foundation can be transferred to OTC channels
.
Out-of-hospital clinics and pharmacies are different from in-hospital sales.
Whether they can sell well depends on whether the product attributes are suitable for sales outside the hospital
.
At present, some Chinese medicine companies have shifted their targets to markets outside medical insurance
.
A pharmaceutical company mentioned on the interactive platform that in addition to hospitals, OTC and e-commerce channels are also important channels for market expansion.
In the future, it will increase the development of new products and echelon products, improve product structure, and cultivate new profit growth points
.
The sales of many Chinese medicine injections of Pharmaceutical Company B were frustrated because they entered the key monitoring catalogue
.
In 2018, the company embarked on the road of transformation, from a sales company to a technology company, and its main products were transformed from proprietary Chinese medicines to biological medicines, vaccines, chemical medicines, medical devices , and Internet medicines, and from localization in China to globalization
.
The main response strategy of C company is to create new growth points for oral preparations, increase the growth momentum of oral preparations, and reduce the concentration of contribution to the profit of traditional Chinese medicine injection products.

.
The company once pointed out that traditional Chinese medicine injections have been subject to more and more stringent controls, and supplementary medications and key monitoring catalogs are also ready to be released.
Once the main products are included, it will adversely affect the sales scale
.
It is reported that in recent years, C company has continued to promote the strategic transformation from injection-based to "oral + injection" and prescription promotion to "prescription + OTC".
The current transformation has also driven the company's performance to maintain a growth trend
.